Izipry™

High-dose naloxone rescue medication for synthetic opioid overdose

Opioid overdose is a life-threatening condition marked by respiratory depression and loss of consciousness. Izipry™ is based on the AmorphOX® technology and is a high-dose naloxone rescue medication designed to reverse overdoses from potent synthetic opioids, including fentanyl and its analogues.

Substance

Powder-based naloxone

Development phase

FDA registration

Temperature stability1

≤0.1% after 24 months

Administration

Nasal powder

Leverage established manufacturing processes

Yes

Partnership

Seeking partnership for commercialization in the US

Differentiation and intellectual property

Izipry demonstrates:

  • Formulations have demonstrated significantly faster absorption and higher plasma concentrations of naloxone compared to intramuscular injection.
  • Formulations have demonstrated superior performance in cross-study comparisons with the current market leader, delivering higher peak plasma levels and total exposure, which are critical for preventing brain damage and saving lives.
  • Enhanced stability through the powder formulation, ensuring resilience from sub-zero to above room temperatures, without loss of efficacy. Izipry is protected by patents until 2039, securing long-term exclusivity.

Development reached FDA registration phase

Izipry is in late-stage development. Commercial testing of the final product for reliability and quality is underway. The team is preparing for an expected resubmission to the FDA in Q3 2026, marking a critical milestone toward regulatory approval. The resubmission follows a complete response letter received in 2024, where the FDA required commercial manufacturing data from the final product. Orexo is seeking partnership for commercialization in the US and other markets.

Study testing

Naloxone formulations by AmorphOX compared with Narcan®

Findings: Studies demonstrate that nasal powders formulated with AmorphOX® achieve higher plasma concentrations of naloxone, provide more sustained effects, and are absorbed more rapidly compared to Narcan® liquid nasal spray.

  1. Chemical degradation after accelerated stability studies in 40°C/75% RH. Note: Narcan® is a registered trademarks of Emergent BioSolutions Inc.

Read more

OX472

GLP-1 agonist, semaglutide

OX472 is an innovative intranasal formulation of semaglutide, a GLP-1 receptor agonist, developed using Orexo’s proprietary AmorphOX® technology. Orexo is also exploring AmorphOX with semaglutide for oral administration.

Vaccine

Advancing a new generation of vaccines

Vaccines represent a key research area for Orexo, and early data highlights the potential of AmorphOX® to enable thermostable, needle-free nasal vaccines.

OX390

For overdoses caused by adulterated drugs

OX390 for overdoses caused by adulterated drugs, is developed by Orexo in partnership with the Biomedical Advanced Research and Development Authority (BARDA), which is part of the US department of health and human services.

OX640

Redefining emergency treatment for anaphylaxis

OX640 is Orexo’s innovative intranasal powder formulation of epinephrine, designed to provide rapid onset and reliable dosing for the treatment of severe allergic reactions, including anaphylaxis.

Orexo

Launched products

By applying its specialized drug delivery expertise to well-known active ingredients, Orexo has successfully advanced multiple candidates from development to global commercialization.

Partnership

Partner with us

We power partners´ proprietary projects with the AmorphOX® technology.